Lukas Aguinarte

Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer

Philip Bischoff, Martin Reck, Tobias R. Overbeck et al. · Journal of Thoracic Oncology · 2023 · 42 citations · Full text

Study Design and Rationale for the PACE-LUNG Trial: A Multicenter, Single-Arm, Phase II Clinical Trial Evaluating the Efficacy of Additional Chemotherapy for Patients with EGFRm NSCLC with the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib First-Line Treatment

Fabian Acker, Lukas Aguinarte, Friederike Althoff et al. · Clinical Lung Cancer · 2022 · 10 citations